Reversibility of Tamoxifen® Retinopathy—A Ten-Year Follow-Up

REFERENCES

• Heel R C, Brogden R N, Speight T M, Avery G S. Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs 1978; 16: 1–24
   PubMed Web of Science ®Google Scholar
• Ashford A R, Donev I, Tiwari R P, Garrett T J. Reversible ocular toxicity related to tamoxifen therapy. Cancer 1988; 61: 33–35
   PubMed Web of Science ®Google Scholar
• Nayfield S G, Gorin M B. Tamoxifen-associated eye disease. A review. J Clin Oncol 1996; 14(3)1018–1026
   PubMedGoogle Scholar
• Chern S, Danis R P. Retinopathy associated with low-dose tamoxifen. (letter). Am J Ophthalmol 1993; 116: 372–373
   PubMedGoogle Scholar
• Griffiths M FP. Tamoxifen retinopathy at low dosage. (letter) Am. J Ophthalmol 1987; 104: 185–186
   PubMed Web of Science ®Google Scholar
• Heier J S, Dragoo R A, Enzenauer R W, Waterhouse W J. Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol 1994; 117: 772–775
   PubMed Web of Science ®Google Scholar
• Pavlidis N A, Petris C, Briassoulis E, et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer 1992; 69: 2961–2964
   PubMed Web of Science ®Google Scholar
• Vinding T, Nielsen N V. Retinopathy caused by treatment with tamoxifen in low dosage. Acta Ophthalmol 1983; 61: 45–50
   Google Scholar
• Marmor M F, Holder G E, Seeliger M W, Yamamoto S. Standard for clinical electroretinography (2004 update). Doc Ophthalmol 2004; 108: 107–114
   PubMed Web of Science ®Google Scholar
• Kretschmann U, Gendo K, Seeliger M, Zrenner E. Multifocal ERG recording by the VERIS technique and its clinical applications. Macular and Retinal Diseases, P Wiedemann, L Kohen. Karger, Basel 1997; 29: 8–14, Dev Ophthalmol
   Google Scholar
• Kretschmann U, Usui T, Ruether K, Zrenner E. Electroretinographic campimetry in a patient with crystalline retinopathy. German J Ophthalmol 1997; 5: 399–403
   Google Scholar
• Ah Song R, Sasco A J. Tamoxifen and ocular toxicity. Cancer Detect Prev 1997; 21: 522–531
   PubMedGoogle Scholar
• Gorin M B, Day R, Costantino J P, Fisher B, Redmond C K, Wickerham L, Gomolin J E, Margolese R G, Mathen M K, Bowman D M, Kaufman D I, Dimitrov N V, Singerman L J, Bornstein R, Wolmark N, Kaufmann D. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 1998; 125: 493–501
   PubMed Web of Science ®Google Scholar
• Kaiser-Kupfer M I, Lippmann M E. Tamoxifen retinopathy. Cancer Treat Rep 1978; 62: 315–320
   PubMedGoogle Scholar
• McKeown C A, Swartz M, Blom J, Maggiano J M. Tamoxifen retinopathy. Br J Ophthalmol 1981; 65: 177–179
   PubMed Web of Science ®Google Scholar
• Noureddin B N, Seoud M, Bashshur Z, Salem Z, Shamseddin A, Khalil A. Ocular toxicity in low-dose tamoxifen: a prospective study. Eye 1999; 13: 729–733
   PubMed Web of Science ®Google Scholar
• Sadowski B, Kriegbaum C, Apfelstedt-Sylla E. Tamoxifen side-effects, age-related macular degeneration (AMD) or cancer associated retinopathy (CAR). Eur J Ophthalmol 2001; 11: 309–312
   PubMedGoogle Scholar
• Tang R, Shields J, Schiffman J, Li H, Locher D, Hampton J, Prager T, Pardo G. Retinal changes associated with tamoxifen treatment for breast cander. Eye 1997; 11: 295–297
   PubMed Web of Science ®Google Scholar
• Therssen R, Jansen E, Leys A, Rutten J, Meyskens J. Screening for tamoxifen ocular toxicity: A prospective study. Eur J Ophthalmol 1995; 5: 230–234
   PubMedGoogle Scholar
• Parkkari M, Paakkala A M, Salminen L, Holli K. Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. Acta Ophthalmol Scand 2003; 81: 495–499
   PubMedGoogle Scholar
• Hood D C, Frishman L J, Saszik S, Viswanathan S. Retinal origins of the primate multifocal ERG: implications for the human response. Invest Ophthalmol & Vis Sci 2002; 43: 1673–1685
   PubMed Web of Science ®Google Scholar
• Kuchenbecker J, Pump-Schmidt C, Olbricht S, Weise W, Behrens-Baumann W. Electrophysiological studies in breast carcinoma patients with tamoxifen retinopathy. Ophthalmologe 2001; 98(1)81–85
   PubMedGoogle Scholar
• Gualino V, Cohen S Y, Delyfer M N, Sahel J A, Gaudric A. Optical coherence tomography findings in tamoxifen retinopathy. Am J Ophthalmol 2005; 140: 757–758
   PubMed Web of Science ®Google Scholar
• Bourla D H, Sarraf D, Schwartz S D. Peripheral retinopathy and maculopathy in high-dose tamoxifen therapy. Am J Ophthalmol 2007; 144: 126–128
   PubMed Web of Science ®Google Scholar
• Eisner A, Austin D F, Samples J R. Short wavelength automated perimetry and tamoxifen use. Br J Ophthalmol 2004; 88: 125–130
   PubMed Web of Science ®Google Scholar
• Toimela T, Tahti H, Salminen L. Retinal pigment epithelium cell culture as a model for evaluation of the toxicity of tamoxifen and cloroquin. Ophthalmic Res 1995; 27: 150–153
   PubMedGoogle Scholar
• Maenpaa H, Gegelashvili G, Tahti H. Expression of glutamate transporter subtypes in cultured retinal pigment epithelial and retinoblastoma cells. Curr Eye Res 2004; 28: 159–165
   PubMed Web of Science ®Google Scholar
• Mannerstrom M, Zorn-Kruppa M, Diehl H, Engelke M, Toimela T, Maenpaa H, Huhtala A, Uusitalo H, Salminen L, Pappas P, Marselos M, Mantyla M, Mantyla E, Tahti H. Evaluation of the cytotoxicity of selected systemic and intravitreally dosed drugs in the cultures of human retinal pigment epithelial cell line and of pig primary retinal pigment epithelial cells. Toxicol in Vitro 2002; 16: 193–200
   PubMedGoogle Scholar
• Engelke M, Tykhonova S, Zorn-Kruppa M, Diehl H. Tamoxifen induced changes in the lipid composition of the retinal pigment epithelium cell line D407. Pharmacol Toxicol 2002; 91: 13–21
   PubMedGoogle Scholar